GIS:FRA
Gilead Sciences
130,88 €
arrow_upward
+0,28%(+0,36) 1K
9-okt, 22:00:00 (GMT+2) · EUR
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoGIS tikeri uchun statistika yaratilmoqda...
Ochish
130,88 €
Yuqori
130,88 €
Past
130,88 €
Bozor kapitali
187,44 mlrd
Oʻrtacha hajm
398,00
Hajmi
0,00
52 haftalik eng yuqori
134,58 €
52 haftalik eng past
97,79 €
Xodimlar soni
17 ming
Ochish
130,88 €
Yuqori
130,88 €
Past
130,88 €
Bozor kapitali
187,44 mlrd
Oʻrtacha hajm
398,00
Hajmi
0,00
52 haftalik eng yuqori
134,58 €
52 haftalik eng past
97,79 €
Xodimlar soni
17 ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Yahoo Finance
·
6 soat oldin
Gilead Has Outperformed the S&P 500. But is its Valuation Still Attractive?
Yahoo Finance
·
1 kun oldin
Why Is Everyone Ignoring Gilead Stock's High Cash Yield?
MarketBeat
·
3 kun oldin
Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says
Yahoo Finance
·
1 oy oldin
Pfizer vs. Gilead: Which Drugmaker Has the Stronger Growth Story?
Profil
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Gilead Sciences haqida
CEODaniel O'Day
Xodimlar soni17 ming
Asos solingan22-iyn, 1987
Bosh ofislarFoster City, Kaliforniya, Amerika Qo‘shma Shtatlari
Sektor-
Veb-saytgilead.com